(5) Update on Osteoporosis: Role of Romosozumab

Abstract

In recent years, osteoporosis has become a serious concern in developed countries. Romosozumab, launched in 2019, is a relatively new osteoporosis medication that enhances bone mineral density and inhibits development of new fractures. Contraindications to romosozumab administration include hypocalcemia. It should also be administered with caution to patients at a high risk of cardiovascular disorders. To maximize its effects, it is preferable to administer romosozumab before initiation of other osteoporosis medications. Currently, no clinical reports have discussed the ability of romosozumab to promote fracture healing. Combination therapy using romosozumab and other drugs may be useful in patients with osteoporosis.